Browsing by Author "Vinod K. Yadav"

Now showing 1 - 2 of 2

Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis on Fibrosis and Severity of Liver Disease: A Real Life Experience from a Tertiary Care Center of North India
(Elsevier B.V., 2018) Gaurav Garg; Vinod K. Dixit; Sunit K. Shukla; Sudhir K. Singh; Shivam Sachan; Anurag Tiwari; Vinod K. Yadav; Dawesh P. Yadav
Background/aims: Treatment of chronic hepatitis C infection with direct-acting antiviral (DAA) drugs has been highly effective, but data regarding benefit in advanced liver disease is relatively scarce in Indian patients. The aim of this study was to determine the effects of DAA in patients with HCV related cirrhosis (compensated/decompensated) who achieved sustained virological response post-therapy at 12 weeks (SVR12). Methods: Sixty-three patients with HCV related cirrhosis treated with sofosbuvir based regimen were evaluated. Data regarding baseline demographics, the severity of liver disease and treatment regimen were collected. The primary end point was to evaluate the effect of treatment (SVR12) on the severity of liver disease with the secondary end point being to observe for any adverse events related to treatment. Results: Treatment naïve patients with HCV cirrhosis either due to genotype 1 or genotype 3 were divided into two groups: group A (compensated cirrhosis), group B (decompensated cirrhosis). SVR12 in group A was 91.66% (33/37) and in group, B was 73.17% (30/41). Baseline mean liver stiffness measurement (LSM) in group A was 16.81 ± 3.57 kPa which decreased to 11.19 ± 1.75 kPa at SVR12 (P-value <0.0001). Baseline mean APRI and FIB-4 score in group A were 1.228 ± 0.499 and 2.61 ± 1.06 and in group B were 2.156 ± 1.10 and 5.71 ± 2.06 respectively which decrease to 0.415 ± 0.115 and 1.25 ± 0.46 in group A, to 0.759 ± 0.275 and 2.60 ± 1.12 in group B following SVR12 (P value <0.0001). Mean MELD-Na improved from baseline 9.93 ± 2.04, 20.70 ± 4.52 to 7.21 ± 0.92, 14.23 ± 4.51 respectively in group A and B at SVR12 (P-value <0.0001). Child–Turcotte–Pugh score improved by 1 in 27.27% (9/33) and ≥2 in 76.67% (23/30) of patients in group A and group B respectively. Conclusion: There was a significant improvement in severity of liver disease as depicted by the decrease in LSM and other noninvasive marker of fibrosis in patients who achieved SVR12 on DAA therapy. © 2017 INASL
Reactivity of triazolyl Schiff bases with Ru(II)-2,2′-bipyridyl: Synthesis, spectroscopic characterization of isomers and their photo-physical properties
(Elsevier Ltd, 2009) Vinod K. Yadav; Sanjib Kar; L. Mishra
The condensation of 3-amino-1H-1,2,4-triazole with benzaldehyde and terephthalaldehyde provides the bidentate and tetradentate Schiff bases 1,2,4-triazolo-3-imino-benzene L1H and 1,4-bis(1,2,4-triazolo-3-imino)benzene L2H2, respectively. The well characterized Schiff bases were allowed to react with cis-Ru(bpy)2Cl2 · 2H2O. Isomers of the mononuclear complexes Ru(bpy)2L1]PF6 · NH4PF6 (1a, N4) and [Ru(bpy)2L1]PF6 · 0.5NH4PF6 (1b, N2), and the dinuclear Ru(II) complexes [Ru(bpy)2L2Ru(bpy)2](PF6)2 · NH4PF6 (2a, N4N4), [Ru(bpy)2L2Ru(bpy)2](PF6)2 · NH4PF6 · 2H2O (2b, N2N2) and [Ru(bpy)2L2Ru(bpy)2](PF6)3 · NH4PF6 (2c, Ru(II)-Ru(III)) were separated by column chromatography and characterized by their elemental analysis, FAB mass and spectral (IR, NMR, UV-Vis) data. The data obtained suggest that the ligands are bound to the metal centre via the N4 and N2 atoms of the triazole moiety along with the N (imine) atom. The complexes display metal-to-ligand charge-transfer (MLCT) transitions in the visible region from the dπ(RuII) → π*L transition. Highly intense ligand-based π→π* transitions are observed in the UV region. A dual emission occurs from the N2 and N2N2 isomers. © 2008 Elsevier Ltd. All rights reserved.